Closely-held Soricimed Biopharma received $500,000 in funding from the Government of Canada to support the company’s continued research and development work.
The Government of Canada provided the repayable contribution through the Atlantic Canada Opportunities Agency’s (ACOA) Regional Relief and Recovery Fund, which is supporting businesses during COVID-19.
“We at Soricimed Biopharma are very grateful for the support we are receiving from ACOA during these challenging times,” Robert Bruce, Soricimed’s CEO, said in a statement.
“This funding enables us to continue to move our world-class science closer to commercialization and pursue emerging opportunities. We are proud to champion the strengths of Atlantic Canada as we work globally, such as what we are currently doing with the investigator-initiated human clinical trial of our lead drug candidate, SOR-C13 at the MD Anderson Cancer Center in Houston, Texas,” he added.
